TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02660164

Intervention type: DEVICE
Intervention: Nautilus BrainPulse Recording
Description: Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).

Intervention type: DEVICE
Intervention: Nautilus BrainPulse Recording
Description: Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
Study: NCT03149172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equimatrix®
Description: Ridge preservation bone grafting after tooth extraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Oss®
Description: Ridge preservation bone grafting after tooth extraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobon®
Description: Ridge preservation bone grafting after tooth extraction
Study: NCT02307058

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LEAD RT
Description: The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HEIGHT RT
Description: The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
Study: NCT01317251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (without dairy products)
Description: Control diet without dairy products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (high milk content)
Description: Diet with a high content of milk (\~1200 mg Ca/d from milk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention (high cheese content)
Description: Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
Study: NCT02538042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
Study: NCT02587117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Study: NCT02538042

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Patch
Description: Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM Nicotine Research Cigarettes (0.07 mg)
Description: For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.

Intervention type: DRUG
Group type: OTHER
Intervention: SPECTRUM Nicotine Research Cigarettes (0.07 mg)
Description: For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCE+
Description: During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MCE-
Description: During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
Study: NCT03026881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 20,30,40mg twice daily,capsule oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous injection
Study: NCT03854799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study: NCT05301725

Intervention type: OTHER
Intervention: PPI regimen
Description: All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
Study: NCT03854799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EXTERNAL---BEAM IRRADIATION 50.4 GY
Description: Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study: NCT00016328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00217217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Description: variable-setting low-frequency MRI
Study: NCT05301725

Intervention type: OTHER
Intervention: P-CAB regimen
Description: All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
Study: NCT01596517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin for HCV genotype 1
Description: Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
Study: NCT00217217

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Description: variable-setting low-frequency MRI
Study: NCT04671264

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sallowing VC during six weeks
Description: follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sallowing VC during six weeks
Description: follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl).
Study: NCT03724929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectosigmoidoscopy
Description: Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
Study: NCT03896802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological assesment
Description: 1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological assesment
Description: 1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine.
Study: NCT02720796

Intervention type: OTHER
Group type: OTHER
Intervention: PDX drug sensitivity testing
Description: Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
Study: NCT00031096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid Gel 15% (Finacea, BAY39-6251)
Description: Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel (SH H 655 PBA)
Description: Vehicle gel (SH H 655 PBA) applied topically two times per day.
Study: NCT03869905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first then Aquamin®
Description: 4 capsules per day; 2 to be taken in the morning and 2 in the evening
Study: NCT02452008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: 150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
Study: NCT03971422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT01596517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
Description: Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
Study: NCT03971422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time points.
Study: NCT04463992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program participants
Description: The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by local oncologists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study: NCT03628534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline Enhanced Radiofrequency (SERF) ablation
Description: Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Study: NCT01565655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03226574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
Study: NCT02478216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
Study: NCT01535209

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: 18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy (WBRT)
Description: 10 x 3 Gy to whole brain
Study: NCT05623826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive- behavioral imagery-based training
Description: The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
Study: NCT03583801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory aromatherapy
Description: 2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without aromatherapy
Description: no intervention
Study: NCT00283621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp (darbepoetin alfa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (pegfilgrastim)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study: NCT02481297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein given on Day 1 of each 28 day cycle.
Study: NCT00283621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study: NCT02842736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerene(R) Cryotherapy Device
Study: NCT02481297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein given on Day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
Study: NCT00820469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375
Description: rituximab 375 mg/m2 IV weekly, during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab 1000
Description: rituximab 1000 mg IV, two infusions on day 1 and day 15
Study: NCT03265626

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2: Awareness creation and community mobilization
Description: Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative

Intervention type: OTHER
Group type: OTHER
Intervention: available standard care
Description: The standard care will be maintained but no other additional intevvenion designed by this study
Study: NCT05703529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care means treating as usual, including a regular home visit.